Skip to main
ARDT

ARDT Stock Forecast & Price Target

ARDT Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 33%
Hold 33%
Sell 8%
Strong Sell 0%

Bulls say

Ardent Health is a growing healthcare services company that operates in eight different states across the U.S. Their recent quarter results have exceeded expectations, driven by successful payer contract renegotiations and a strategic IMPACT program that offset weaker surgical volumes. Furthermore, the company's focus on investments in services and technologies, as well as its differentiated joint venture strategy, provide growth potential. Additionally, the company's strong balance sheet and efforts to achieve cost savings and efficiencies position it well for future earnings growth.

Bears say

Ardent Health is facing two main challenges: a decrease in lower-margin procedures and an increase in out-of-hospital settings for certain procedures due to changes from the CMS, which will result in negative financial impacts that management is trying to mitigate through targeted denial management and a joint venture strategy. Even though volume trends have improved, professional fees and payer denial trends remain stable and will contribute to slowing growth. Additionally, the company's exchange headwind trends, while manageable, could prove to be more unfavorable than originally expected. Lastly, Ardent's market and growth strategy may be under-appreciated by the market, presenting a potential opportunity for multiple expansion.

ARDT has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardent Health Partners LLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardent Health Partners LLC (ARDT) Forecast

Analysts have given ARDT a Buy based on their latest research and market trends.

According to 12 analysts, ARDT has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardent Health Partners LLC (ARDT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.